Red Flags Suggesting Cardiac Transthyretin Amyloidosis (ATTR) in Clinical Practice
Abstract
Abstract: Cardiac wtATTR is caused by extracellular deposition of misfolded proteins in the heart. It mostly affects elderly men and is still clearly underdiagnosed. Recognizing red flags suggesting wtATTR is key for a timely diagnosis, enabling the patient to profit from effective therapies. If general practitioners suspect cardiac amyloidosis, it is crucial to rapidly exclude AL-amyloidosis by immunoelectrophoresis, immunofixation as well as light-chain assay, because AL-amyloidosis needs urgent hematologic therapy. After that, the patient should be referred to the cardiologist for further assessment.
Zusammenfassung: Die kardiale wtATTR wird durch extrazelluläre Ablagerungen von fehlgefalteten Proteinen im Herzen verursacht. Sie betrifft meist ältere Männer und wird immer noch deutlich unterdiagnostiziert. Das Erkennen von Anzeichen, die auf wtATTR hindeuten, ist entscheidend für eine rechtzeitige Diagnose, damit der Patient von wirksamen Therapien profitieren kann. Wenn der Hausarzt den Verdacht auf eine kardiale Amyloidose hat, ist es wichtig, eine AL-Amyloidose durch Immunelektrophorese, Immunfixation und Leichtkettenbestimmung rasch auszuschliessen, da die AL-Amyloidose einer dringlichen hämatologischen Therapie bedarf. Danach sollte der Patient zur weiteren Abklärung an eine Kardiologin/einen Kardiologen überwiesen werden.
Résumé: La wtATTR est causée par le dépôt extracellulaire de protéines mal repliées dans le cœur. Elle touche principalement les hommes âgés et est encore nettement sous-diagnostiquée. Reconnaître les signaux d’alarme suggérant une wtATTR est essentiel pour un diagnostic rapide, permettant au patient de bénéficier de thérapies efficaces. Si les médecins généralistes suspectent une wtATTR, il est crucial d’exclure rapidement une AL-amyloïdose par immunoélectrophorèse, immunofixation ainsi que par le dosage de la chaîne légère, car l’AL-amyloïdose nécessite un traitement hématologique urgent. Ensuite, le patient doit être adressé au cardiologue pour une évaluation plus approfondie.
Abbreviations
AL Amyloid light-chain
ATTR Transthyretin amyloidosis
CMR Cardiac magnetic resonance imaging
ECG Electrocardiogram
NT-proBNP N-terminal fragment of prohormone brain natriuretic peptide
TTR Transthyretin
vATTR Hereditary/variant transthyretin amyloidosis
wtATTR Wild-type transthyretin amyloidosis
Cardiac amyloidosis
Amyloidosis is not a single disease but a group of diseases sharing a common feature: the extracellular deposition of misfolded, insoluble, fibrillar proteins in organ tissues [1, 2]. In the 19th century, the botanical term amyloid, meaning starch or cellulose, was adopted to describe abnormal extracellular material in the liver [3]. Even though generaly considered a systemic disease, organ manifestation patterns vary between different types of amyloidosis. While multiple proteins are known to be capable of aggregating as amyloid, there are three relevant types of amyloidosis mainly affecting the heart (Figure 1): light-chain (AL) amyloidosis, hereditary/variant transthyretin amyloidosis (vATTR), and wild-type transthyretin amyloidosis (wtATTR), formerly known as senile amyloidosis. AL amyloidosis derives from misfolded immunoglobulin light chains as a result of a monoclonal gammopathy. It is a very serious, rapidly progressing, and irreversible disease which requires prompt diagnosis and therapy of the hematologic disease to avoid unfavorable prognosis [4, 5]. The second common type, transthyretin (TTR) amyloidosis, results from accumulation of the transport protein TTR, which is produced in the liver [1]. The hereditary form vATTR is a very rare disease, deriving from a mutated form of TTR, prone to misfolding. Depending on the mutation, the clinical picture may involve the heart, however it usually mainly affects the peripheral nervous system [6].
Even though its prevalence is unknown, it seems more and more obvious that wtATTR is the most common form of cardiac amyloidosis [1]. These patients, in most cases men over 60 years of age, usually present with heart failure, atrial fibrillation or stroke due to ATTR cardiomyopathy. However, also other organs can be affected, sometimes causing polyneuropathy and in most cases orthopedic problems. Often, the diagnosis is established rather late, since patients develop heart failure symptoms only after the deposition of large amounts of amyloid in the heart muscle. However, elevation of cardiac biomarkers as well as surgery for orthopedic/neurological problems – in particular bilateral carpal tunnel syndrome – often manifest years before this stage (Figure 2).
Due to the lack of therapeutic options the awareness of ATTR has stayed low for many decades, but in recent years novel and effective therapeutic concepts have been introduced, [7, 8] of which several are available in Switzerland [6]. Tafamidis in particular has been observed to have an impressive beneficial effect on mortality and morbidity in wtATTR as well as vATTR patients [9]. To ensure that patients can profit from these effective and evidence-based therapies, it is crucial to identify patients at risk and to establish the correct diagnosis.
Red Flags
Given the systemic nature of the disease, it is not surprising that red flags indicating cardiac amyloidosis can involve cardiac findings as well as extracardiac findings. Cardiac red flags (Figure 3) include signs and symptoms of heart failure (usually with preserved ejection fraction), a pathologic electrocardiogram (ECG), troponin elevation, elevated N-terminal fragment of prohormone brain natriuretic peptide (NT-proBNP), and typical findings in the echocardiogram as well as cardiac magnetic resonance imaging (CMR). ECG changes are non-specific and often include pseudo-infarction patterns (Q waves), poor R-progression in the precordial leads, and sometimes (but not so frequently) peripheral low voltage. Since the conduction system is also affected, high-grade atrioventricular block and bundle branch block are common [10]. Atrial amyloid causes atrial dysfunction leading to a high susceptibility to thrombus formation (even in sinus rhythm) as well as atrial tachycardia, atrial flutter, and very commonly atrial fibrillation. The echocardiogram typically reveals hypertrophied left and right ventricular walls (due to the amyloid deposition in the muscle) and relevant diastolic dysfunction. Strain analysis, assessing left ventricular myocardial deformation, very commonly exhibits a strain preservation pattern in the left ventricular apex with marked impairment at the base, called apical sparing or cherry-on-top sign [11]. In CMR, a typical patchy late gadolinium enhancement pattern is present [12]. Bone scintigraphy showing radiotracer uptake in the heart is part of the diagnostic algorithm for ATTR [13]. However, if conducted for other reasons, a cardiac signal can suggest cardiac ATTR as a coincidental finding.
Extracardiac red flags (Figure 4) include different musculoskeletal problems and polyneuropathy. Carpal tunnel syndrome affects >50% of wtATTR patients, is usually bilateral and requires surgery. Interestingly, the respective symptoms and surgery often precede the onset of heart failure by about eight years [14]. Recent studies found amyloid deposits in the excised tissue from the carpal tunnel, emphasizing the potential for early diagnosis prior to the development of cardiac symptoms [15]. Other common orthopedic problems are lumbar spinal stenosis and biceps tendon rupture [16]. In addition, patients with wtATTR need knee and hip arthroplasty three to five times more often and earlier than age- and sex-matched controls [17]. Furthermore, peripheral neuropathy (which is usually the main finding in vATTR) may also be present in wtATTR. It is most commonly symmetric, sensory, and might be easily missed [18].
Another very typical feature of ATTR patients is the intolerance of antihypertensive or heart failure medication, often because of orthostatic problems. In particular, betablockers are poorly tolerated because the augmentation of cardiac output depends on the ability to increase the heart rate due to the fixed and low stroke volume in ATTR. In addition, ATTR can be suspected in patients who needed antihypertensive medication for many years but begin to show normal or low blood pressure with age (caused by cardiac dysfunction).
- •Cardiac amyloidosis is often detected late or not at all. Effective therapies are available, and it is important to know the “red flags” that may be indicative at an early stage.
- •In particular, heart failure (with preserved ejection fraction) in combination with bilateral carpal tunnel syndrome should trigger the suspicion of wtATTR.
- •If cardiac amyloidosis is suspected, the first step must be a rapid search for AL amyloidosis (by immunoelectrophoresis/fixation and free light chain assay), as this disease requires urgent hematologic evaluation and therapy.
Study questions
- 1.Which statement about cardiac amyloidosis is correct?
- a)The most common form of cardiac amyloidosis is due to monoclonal free light chains.
- b)The first clinical sign of wtATTR is usually a symmetric polyneuropathy.
- c)Most cases of TTR amyloidosis are genetic and thus heritable.
- d)wtATTR predominantly affects men over 60 years of age.
- 2.Which statement about cardiac amyloidosis is correct?
- a)AL amyloidosis usually does not require a specific therapy.
- b)No therapies are yet available in Switzerland for TTR amyloidosis.
- c)Orthopedic problems often lead to surgical intervention in wtATTR years before cardiac problems occur.
- d)Carpal tunnel syndrome is common in wtATTR, but surgery is usually not necessary.
Answers to the study questions
1. Answer d) is correct.
2. Answer c) is correct.
Bibliography
Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2019;73(22):2872–2891.
.Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. Circulation. 2017;135(14):1357–1377.
.Über eine im Gehirn und Rückenmark des Menschen aufgefundene Substanz mit der chemischen Reaction der Cellulose. Archiv f pathol Anat. 1854;6:135–138.
.AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. Journal of the American College of Cardiology. 2016;68(12):1323–1341.
.Expert recommendation from the Swiss Amyloidosis Network (SAN) for systemic AL-amyloidosis. Swiss Med Wkly. 2020;150:w20364.
,Management of transthyretin amyloidosis. Swiss Med Wkly. 2021;151:w30053.
,Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. The New England journal of medicine. 2018;379(1):11–21.
,Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. The New England journal of medicine. 2018;379(1):22–31.
,Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. The New England journal of medicine. 2018;379(11):1007–1016.
,Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. The American journal of cardiology. 2005;95(4):535–537.
.Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. European heart journal. 2020;41(14):1439–1447.
,Magnetic Resonance in Transthyretin Cardiac Amyloidosis. Journal of the American College of Cardiology. 2017;70(4):466–477.
,Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. Journal of the American College of Cardiology. 2005;46(6):1076–1084.
,Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type Transthyretin: A Prospective, Observational Cohort Study. Circulation. 2016;133(3):282–290.
,Wild-type transthyretin-derived amyloidosis in various ligaments and tendons. Hum Pathol. 2011;42(9):1259–1264.
,Association Between Ruptured Distal Biceps Tendon and Wild-Type Transthyretin Cardiac Amyloidosis. JAMA. 2017;318(10):962–963.
.Hip and knee arthroplasty are common among patients with transthyretin cardiac amyloidosis, occurring years before cardiac amyloid diagnosis: can we identify affected patients earlier? Amyloid. 2017;24(4):226–230.
,Utility of Neuropathy Screening for Wild-Type Transthyretin Amyloidosis Patients. Can J Neurol Sci. 2021;48(5):607–615.
.